Author
@Pharmdca Pharmdca
grade Cx.com/Pharmdca ↗
Long-only dip-buying biotech-and-megacap-tech bull who discloses every entry
Posts real-time, ticker-specific add/trim/buy-the-dip disclo
trader score
-1.50
hit rate
50%
mean α
-0.74%
signals 14d
48
Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY.
Their picks, scored
Across their last 20 scored bets: 50% hit rate, -0.74% mean alpha, trader score -1.50. Their last-14d mentions, direction-adjusted, have moved +1.5% since posting (mean over 36 mentions with price data).
Recent signals15receipts included
| date (PT) | ticker | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|---|
| 2026-07-02 | XBI | @Pharmdca | +0.25 | Biotech pullback strategy: trimmed on uptick, raise cash, buy good dips selectively. | — | tweet ↗ |
| 2026-07-02 | MSFT | @Pharmdca | +0.25 | Says MSFT needs a break over $400. | — | tweet ↗ |
| 2026-07-02 | TSLA | @Pharmdca | -0.25 | Notes TSLA down big even after delivery numbers; author has no position. | — | tweet ↗ |
| 2026-07-02 | META | @Pharmdca | +0.75 | Bought more META 2028 LEAPS — Author says they bought more META LEAPS expiring in 2028. | — | tweet ↗ |
| 2026-07-01 | RDDT | @Pharmdca | +0.80 | Long RDDT; $200 almost here with breakout soon — Explicit long RDDT with $200 near target and breakout/momentum call. | -1.6% | tweet ↗ |
| 2026-07-01 | META | @Pharmdca | +0.65 | META gap fill toward $680; RDDT breakout — Forward upside chart calls for META and RDDT. | -4.9% | tweet ↗ |
| 2026-07-01 | RDDT | @Pharmdca | +0.60 | META gap fill toward $680; RDDT breakout — Forward upside chart calls for META and RDDT. | -1.6% | tweet ↗ |
| 2026-07-01 | RDDT | @Pharmdca | +0.35 | RDDT needs breakout over $200 after repeated selloffs near $180 pivot. | -1.6% | tweet ↗ |
| 2026-07-01 | XBI | @Pharmdca | -0.15 | Author says they trimmed several biotech positions to lock profits and wait for dips. | +2.5% | tweet ↗ |
| 2026-07-01 | AMZN | @Pharmdca | +0.65 | Explicitly bought more AMZN and NVDA positions. | +0.4% | tweet ↗ |
| 2026-07-01 | NVDA | @Pharmdca | +0.65 | Explicitly bought more AMZN and NVDA positions. | -1.4% | tweet ↗ |
| 2026-07-01 | META | @Pharmdca | +0.65 | META is now biggest position with accumulated shares and 2028 LEAPS. | -4.9% | tweet ↗ |
| 2026-07-01 | · | @Pharmdca | · | General investing framework: buy opportunities, ignore volatility, maintain discipline. | · | tweet ↗ |
| 2026-07-01 | META | @Pharmdca | +0.75 | Bullish on META reversal and names tech opportunities as cheap shares before momentum resumes. | -4.9% | tweet ↗ |
| 2026-07-01 | NOW | @Pharmdca | +0.55 | Bullish on META reversal and names tech opportunities as cheap shares before momentum resumes. | +0.5% | tweet ↗ |
Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.